Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (2142)	6/5/2003 12:22:34 PM
From: JoeinIowa	Read Replies (1) \| Respond to of 23958

Ken, My TRIB is like your CDIC. Sooner or later it will get the attention it deserves. Joe News for 'TRIB' - (J.M. Dutton & Associates Announces Investment Opinion: Trinity Biotech Strong Buy Rating Maintained by Dutton & Associates) EL DORADO HILLS, Calif., Jun 5, 2003 (BUSINESS WIRE) -- J.M. Dutton & Associates issues its quarterly update coverage of Trinity Biotech (Nasdaq:TRIB) maintaining a Strong Buy rating. The 7-page report by J.M. Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com, and from Bloomberg (JMDA), First Call, Zacks, Multex, and other leading financial portals. Trinity develops, acquires, manufactures, and markets diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. Its broad line of test kits are mostly used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Its UniGold(TM) HIV test has the potential to become Trinity's single most important product. Trinity completed its submission to the FDA in late March, and is hopeful of receiving marketing clearance for UniGold(TM) by quarter end. The Company's near term outlook is very favorable, as indicated by our projected 2003 sales of $69 million and EPS of $.175, representing gains of 32.7% and 46.0% respectively. The stock remains undervalued, in our opinion, and we have raised our 12-month price target to $3.25. Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 19 analysts, primarily CFAs, have expertise in many industries including healthcare, technology, finance, banking, retailing, food, gaming, and energy. We provide continuing analyst coverage of over 60 enrolled companies, and our institutional-quality research, estimates, and ratings are carried in all the major databases serving institutions and online investors.